Chordate Medical is currently in Helsinki to present the migraine treatment Ozilia® at the Finnish Neurology Association’s congress, taking place from November 1st to 3rd. The congress is gathering 450 delegates from across Finland.
![](https://www.chordate.com/wp-content/uploads/2023/11/Chordate-Medical-2-1024x862.jpg)
“We are met with significant interest from numerous migraine specialists and neurologists. The Ozilia® treatment is considered a necessary and welcome drug-free addition to the treatment arsenal. The Finnish clinics that participated in the migraine study PM007 are a big asset and help in spreading awareness of Ozilia® in the country,” says Anders Weilandt, CEO of Chordate Medical.
Ozilia® is a CE-marked nerve-stimulating treatment method that offers a drug-free alternative for chronic migraine. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia.